🔶Clinical Year in Review #ACR24 🔶 Talk By Michael Pillinger • Review some of the most impactful studies in Rheumatology from the past year! #RheumTwitter #Rheumatology

🆕 The Great Debate at #ACR24: Is Mixed Connective Tissue Disease (MCTD) a distinct disease entity? 🗳️ Final Vote (n=430 votes) • 51% = MCTD *is* a unique disease • 49% = MCTD is not a unique disease LisaChristopherStine #MCTD #Rheumatology

#ACR24 Lupus Nephritis  • By Dr. Maria Dall'Era UCSF Rheumatology Review of #LupusNephritis 🫘 ▪️Rx TRIPLE therapy ▪️belimumab vs voclosporin ▪️low level proteinuria (even *UPCR <0.5*) can STILL be associated with disease activity (Class III/IV/V) #Lupus #RheumTwitter #NephTwitter

Today is a great day to discover the latest research on #AxSpA #lupus #OA #PsA #RA Sjögren's and more! What are you interested in learning about? #ACR24

How fast should #psoriaticarthritis treatments work? #ACR24 study shows patients who respond in 6 months have less pain, better quality of life, and improved results. AbbVie acrabstracts.org/abstract/benef….

A Mediterranean-style whole food plant-based diet shows promise for #gout and #cardiovascular health in new #ACR24 study: ✅ Lowers serum uric acid ✅ Reduces gout severity and pain ✅ Significant weight loss ✅ Improves LDL cholesterol acrabstracts.org/abstract/effec…

Thank you to the Global Healthy Living Foundation for inviting us to the Clinical Trials Talks Podcast. We’re excited to collaborate & share JuanaMata & Estela Mata's experiences as patient & caregiver. Our goal is to inspire & empower minority communities affected by autoimmune diseases like lupus.

Findings on rheumatoid arthritis & common infections: ✅31% of monthly reports included infection, mostly upper respiratory ✅27% led to RA medication interruptions, higher with severe infections ✅Infections impacted fatigue & work productivity, with possible flare increase

#ACR24 study looked at giant cell arteritis (GCA) in Medicare fee-for-service and found that prevalence: ⬆️Rises with age (highest in 85+) ⬆️Is ~2x higher in females ⬆️Is highest in White persons ⬇️Is lowest in Asian persons @abbVie Peter Merkel cdmcd.co/zE64yY

As you can see here our results are counterintuitive 🤯 #ACR24

🦠 New at #ACR24! Data from rheumatoid arthritis patients & infection risks: ✅ No increased infection risk from biologics, JAK inhibitors, or low-dose steroids ✅ Higher infection rates from winter, rural areas, & past infections ✅ Comorbidities may play a bigger role than

Are you satisfied with your rheumatoid arthritis control? 🤔 A new #ACR24 study reveals: 🩺 73% of 26,377 patients are satisfied, but 57.5% of those not 'very satisfied' want med changes. 🩺 Top concerns: fear new meds won’t work & thinking current meds are 'good enough.'

🎉 100 essays! @ChronicEileen has reached an incredible milestone with CreakyJoints.org, and we couldn’t be more grateful. Eileen, your words have inspired countless patients and amplified the patient voice in ways that truly matter. Thank you for tackling the tough

Do you have fatigue or pain from #lupus (SLE) even on your "good" days? New #ACR24 research showed that 24% of lupus patients experience moderate to severe symptoms even on their "good" days, which greatly impacts quality of life. acrabstracts.org/abstract/impac…

#OverheardatACR24 Angela Degrassi

For Shelley Shelley Fritz, managing RA means becoming her own research expert. At #ACR24, she reveals how structured searches on PubMed helped her address GI symptoms and informed her treatment plan. Discover her empowering story here: creakyjoints.org/acr-2024/syste… #GIHealth

A Milestone of Resilience: Writing 100 Personal Essays About Living with Rheumatoid Arthritis creakyjoints.org/about-arthriti… Eileen Davidson - Rheumatoid Arthritis Advocate

OverheardatACR24 Laura Stradford

Live from sunny D.C. and #ACR24! ☀️ This conference is more than just a meeting — it’s a celebration of hope, progress, and collaboration for those of us living with rheumatic diseases. Together, we’re shaping a brighter future. 🌟💊 #Rheumatology Shilpa Venkatachalam

#ACR24 research on #rheumatoidarthritis patients starting a 1st-line TNF therapy finds: 👉 Most who don’t respond to the treatment at 3 months still don’t respond by 12 months 👉 1 in 4 patients achieving low disease activity/remission at 3 months were no longer at 12 months